Calidi第三季归属普通股股东净亏损360万美元：候选药CLD-401继续推进临床准备
美国加利福尼亚州 San Diego，生物技术企业 Calidi Biotherapeutics 11月13日公布截至 2026 年 9 月 30 日的第三季财务与运营结果。季度归属普通股股东的净亏损为 360 万美元。公司在季内通过随市发售安排的注册直接发行取得总募集额 120 万美元。
研发方面，公司的 RedTail 平台候选药 CLD-401 继续向临床推进，目前处于新药临床试验申请准备阶段，目标适应症包括转移性非小细胞肺癌、头颈癌等实体瘤。公司称，CLD-401 在同基因肿瘤模型中经全身给药显示抗肿瘤活性。
RedTail 是一个可全身给药的溶瘤病毒平台，经工程化包膜设计，用于选择性靶向肿瘤、改造肿瘤微环境，并在肿瘤内高水平表达治疗性基因载荷。
学术交流方面，公司于 10月24日在欧洲肿瘤内科学会 2026 年会上作了两项海报展示，介绍 RedTail 平台进展；同时展示了其原位 T 细胞接合平台的临床前数据，包括靶向 TROP-2 的 CLD-501 与靶向 EpCAM 的 CLD-502。
Calidi 在业绩稿中表示，第三季继续推进 RedTail 平台用于全身与局部给药的开发。公司未在业绩稿中给出下一季度的财务指引。
图中是溶瘤病毒改造肿瘤微环境的机制示意图
Calidi Reports Third-Quarter Net Loss of 3.6 Million Dollars as Lead Candidate CLD-401 Advances Toward Clinic
In San Diego, California, biotechnology company Calidi Biotherapeutics reported on November 13 its financial and operating results for the three months ended September 30, 2026. The net loss attributable to common stockholders for the quarter was 3.6 million dollars. During the quarter the company received 1.2 million dollars in gross proceeds from an at-the-market registered direct offering.
On research, CLD-401, the lead candidate from the company RedTail platform, continued to progress toward the clinic and remains in IND-enabling studies. It targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types. The company said CLD-401 demonstrated anti-tumor activity with systemic administration in syngeneic tumor models.
RedTail is a systemically delivered virotherapy platform featuring an engineered enveloped oncolytic virus designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.
On scientific exchange, the company presented two posters at the European Society for Medical Oncology Congress 2026 on October 24, showcasing data from the RedTail platform, and presented preclinical data from its in situ T-cell engager platform, including the TROP-2-targeted candidate CLD-501 and the EpCAM-targeted candidate CLD-502.
Calidi said it continued throughout the third quarter to advance the RedTail platform for systemic and local delivery. The release gave no financial guidance for the coming quarter.
来源：Calidi Biotherapeutics
发布：GSM·美国（发布链接）
图片来源：图：溶瘤病毒改造肿瘤微环境的机制示意图。作者：Antonio Marchini，CC BY 4.0，维基共享资源。 / Photo: Schematic of an oncolytic virus remodeling the tumor microenvironment. Credit: Antonio Marchini, CC BY 4.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
